Skip to main content

Ocular Melanoma clinical trials at UCSF

2 in progress, 1 open to eligible people

Showing trials for
  • IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

    open to eligible people ages 18 years and up

    This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

    San Francisco, California and other locations

  • Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

    Sorry, in progress, not accepting new patients

    This is an open-label, multi-site, single-arm Phase 2 study of adjuvant nivolumab combined with ipilimumab for the treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria, without evidence of metastatic disease. All patients enrolled to the study will be treated with nivolumab 240 mg IV every 2 weeks plus ipilimumab 1mg/kg IV every 6 weeks. 1 cycle = 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, patient request to discontinue or completion of treatment. Subjects may receive up to 25 doses of nivolumab and 8 doses of ipilimumab

    San Francisco, California and other locations

Our lead scientists for Ocular Melanoma research studies include .

Last updated: